Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Terminated 5Completed 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Other hematologic neoplasm 1Breast 1

Conditions

Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × AEG 35156 × Clear all
NCT01018069 2011-07-13

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Aegera Therapeutics

Phase 2 Terminated
60 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

NCT00558545 2009-12-02

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Aegera Therapeutics

Phase 1/2 Terminated
61 enrolled
Breast

Breast Neoplasms

NCT00557596 2009-12-01

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Aegera Therapeutics

Phase 1/2 Terminated
48 enrolled
Tumor-Agnostic

Carcinoma

NCT00558922 2009-07-30

A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

Aegera Therapeutics

Phase 1/2 Terminated
54 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00385775 2008-08-21

Study of XIAP Antisense for Advanced Cancers

Aegera Therapeutics

Phase 1 Terminated
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡